AbbVie drops Shire bid
This article was originally published in Scrip
Executive Summary
Just hours after Shire said it was waiving the three-day notice period for AbbVie's board to meet to consider its offer for Shire "in order to allow the period of uncertainty for its shareholders, employees and other stakeholders to be reduced," AbbVie's board, with major egg on its face, has announced that it is recommending shareholders vote against the Shire transaction.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.